Navigation Links
Bone and cartilage growth to blame for heart valve disease

Research to be published in the April 18 issue of the Journal of the American College of Cardiology provides the first explanation of an active rather than passive process that leads to heart valve degeneration, furthering a Northwestern researcher's effort to lead a paradigm shift in the medical community's beliefs about the cause of valve disease.

Heart valve disease is caused not by a 'wear and tear' phenomenon, but by an inflammatory process likely triggered by high cholesterol that stimulates certain cells to reprogram into bone cells in the aortic valve and cartilage cells in the mitral valve, says principal investigator Nalini Rajamannan, MD, newly appointed director of the Center for Heart Valve Disease in the Bluhm Cardiovascular Institute of Northwestern Memorial Hospital and assistant professor of medicine, Northwestern University Feinberg School of Medicine, who examined diseased mitral and aortic valves removed during surgery for the study.

"Common wisdom in the medical community has always been that thickening of the mitral valves was part of the aging process as deposits of calcium, a mineral found in the blood, built up on the valves. Therefore, research has never focused on preventing the problem," says Dr. Rajamannan. "Currently the only option is to surgically repair or replace the damaged valves. Our findings open the door to the idea that medical therapies such as statins may be able to play a role in preventing or slowing the process and curtailing the need for surgery."

Valvular heart disease is on the rise with the aging of the United States population, and is second only to coronary artery disease as a cause for open heart surgery. Heart valve disease leads to 100,000 surgeries in the U.S. each year to repair or replace damaged valves. Mitral valve disease is a leading cause of atrial fibrillation, which is a major culprit in strokes and heart failure. Aortic valve disease can lead to heart failure, arrhythmia, in fections in the heart, and sudden death may occur in 15 to 20 percent of people who have symptoms.

Dr. Rajamannan has focused her research for the past seven years on advancing the knowledge of mechanisms of aortic and mitral valve disease using animal models and human studies. "I wanted to know why diseased valves had were hardened with a glassy whitish appearance ?totally different than healthy tissue, which indicated to me that the actual structure of the valves had changed," she says. Dr. Rajamannan has been awarded over $750,000 in grants from the NIH and the American Heart Association to pursue this research.

Dr. Rajamannan's laboratory was the first to treat animals with calcifications in heart valves with medications called statins, the same drugs that are currently used to treat high cholesterol. In an early pioneering study, animals treated with statins had significantly less heart valve disease than the control animals that were not treated. The results from the animal studies and now with the human valves demonstrate that valvular heart disease has an active biology which can be treated with medications similar to that of coronary artery disease.

"As with the majority of people in the field who hear about this research, I was surprised when Dr. Rajamannan's unique observations indicated that the process of valve degeneration is instead an active process, linked to inflammation and cellular growth," says Robert Bonow, MD, co-director of the Bluhm Cardiovascular Institute. "The exciting news is that this line of research suggests that there may be medical treatments in the future that could either treat this disease process."

This research was completed with the support of an American Heart Association Grant-in-Aid (0350564Z) and a grant from the US National Institutes of Health (1K08HL073927-01).

Dr. Rajamannan's research will be featured at the American College of Cardiology's 2006 Heart Valve Summit being hel d June 15-17 in Chicago, which will bring together several of the world's leading cardiologists and cardiac surgeons to provide a comprehensive review of recent advances in the treatment of valvular heart disease.


'"/>

Source:Northwestern Memorial Hospital


Related biology news :

1. Scientists use stem cells to grow cartilage
2. Stem cells from muscles can repair cartilage
3. Bioengineered tissue implants regenerate damaged knee cartilage
4. Signaling for cartilage
5. Woven scaffolds could improve cartilage repair
6. Tissue engineered scaffolding allows reproduction of cartilage tissue
7. Plants, animals share molecular growth mechanisms
8. U-M scientists find genes that control growth of common skin cancer
9. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
10. Researchers discover chemical compounds that affect plant growth
11. Physical and functional interaction of key cell growth molecules linked to cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: